We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Sareum Collaborates with Almirall Prodesfarma

Sareum Collaborates with Almirall Prodesfarma

Sareum Collaborates with Almirall Prodesfarma

Sareum Collaborates with Almirall Prodesfarma

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sareum Collaborates with Almirall Prodesfarma"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sareum Holdings plc has announced that it has entered into a collaborative agreement with Almirall Prodesfarma S.A., to provide protein structure determination capabilities to accelerate drug discovery research at Almirall.

Sareum will utilise its skills in high throughput protein expression, purification and structure determination with the aim of illustrating the precise nature of how Almirall's potential drug candidates interact with their target proteins.

This information will assist Almirall's scientists in their design of new and improved therapeutics against inflammatory diseases.

Sareum's Chief Executive Officer, Dr Tim Mitchell, said: "We are delighted that Almirall has chosen Sareum as their partner in protein structure determination."

He adds, "This is a further important collaboration that Sareum has signed since we started trading on AIM. We look forward to successful delivery of this project to Almirall and to closing additional partnerships such as this."

Almiralls's General Director for Research & Development, Dr José M Palacios, said: "We consider protein structure determination as an essential element in a modern drug discovery strategy, and we have high expectations that this collaboration with Sareum will allow Almirall to significantly leverage its drug discovery capacity."